Aminosalicylates in Inflammatory Bowel Disease in Adults (Review date: July 2020) Page 1
|
|
- Felix Bruce
- 5 years ago
- Views:
Transcription
1 Full Title of Guideline: Author (include and role): Aminosalicylates in Inflammatory Bowel Disease in Adults Natalie Tse- Senior Clinical Pharmacist Dr. Nina Lewis- Consultant Gastroenterologist Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version goes out of date): Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis): Diagnostics and Clinical Support Nursing, Pharmacy and Medical staff July 2020 This guideline is intended to be used in adults receiving aminosalicylate treatment for inflammatory bowel disease within gastroenterology. Changes from previous version (not applicable if this is a new guideline, enter below if extensive): Summary of evidence base this guideline has been created from: N/A European Crohn s & Colitis Organisation Consensus Update 2017 National Institute for Health and Care Excellence (NICE) CG166 (2013), CG152 (2012) British Society of Gastroenterology Guidelines for the management of inflammatory bowel disease in adults for the 2011 Consultation Process Ratification BNF 74 Consultant Gastroenterologists Senior Specialist Pharmacists IBD Specialist Nurses Consultant Nephrologists Ratified by: Dr. Gordon Moran (Consultant Gastroenterologist) Date: 2/11/2017 This guideline has been registered with the trust. However, clinical guidelines are guidelines only. The interpretation and application of clinical guidelines will remain the responsibility of the individual clinician. If in doubt contact a senior colleague or expert. Caution is advised when using guidelines after the review date or outside of the Trust. Page 1
2 Aminosalicylates in Inflammatory Bowel Disease in Adults Objectives: This guideline is intended to provide guidance to healthcare professionals to manage adults (over 18 years old) with inflammatory bowel disease (IBD) who are newly started on or those who are already on 5-aminosalicylate (5-ASA) treatment. Background: 5-Aminosalicylates are recommended for the treatment of mild to moderate ulcerative colitis and the maintenance of remission in ulcerative colitis (UC) 2,4,9. Certain brands of 5-ASA are also licensed for the maintenance of remission in Crohn s ileo-colitis 1,3. The drugs that contain 5-ASA include sulfasalazine, mesalazine, olsalazine and balsalazide. They have different mode of actions (See Table 1 for individual mode of action). The newer 5-ASA s i.e. mesalazine, osalazine and balsalazide are better tolerated than sulfasalazine 2. At Nottingham University Hospitals mesalazine is recommended as the first choice of 5-ASA therapy for patients with IBD 16. Indications 1 : Treatment of mild to moderate ulcerative colitis, acute attack Maintenance of remission of ulcerative colitis Maintenance of remission in Crohn s Disease (CD) and active disease. (Only certain brands are licensed ) Route of administration 1 : Depending on the location of inflammation in the bowel, the 5-ASA can be given: Orally - tablets, granules and suspensions Rectally suppositories, foam and enemas Page 2
3 Formulations 1 : The four currently available 5-ASA drugs are used in several formulations, targeted at specific areas of the bowel. Table 1 Drug Mesalazine Release mechanism 4 Brand Formulation Site of Action 4,7 Timecontrolled Pentasa Tablets Duodenum Granules to rectum release Enema ph dependent release/resin coated Suppositories Octasa Tablets Terminal ileum & colon Salofalk Asacol Asacol MR *Restricted to existing patients only Tablets Granules M/R Enema Foam Enema Tablets Suppositories Terminal ileum & colon Terminal ileum & large bowel (colon & rectum) Balsalazide Olsalazine (Nonformulary) Sulfasalazine (Nonformulary) Mezavant and Ipocol brands are Non-formulary drugs. Delivery by Colazide Capsules Colon carrier molecules, Dipentum Capsules/Tablets Colon with release Generic of 5-ASA after brand splitting by bacterial Salazopyrin Tablets Colon enzymes in Generic Suspension the large brand Suppositories intestine There are differences in licensed indications, dose frequency, interactions, pharmaceutical, pharmacological and pharmacokinetic properties between different formulations. Therefore it is recommended to prescribe the drug by brand name 1. Page 3
4 Octasa and Pentasa brand are generally preferred for new patients as they are more cost effective. There is very little difference in terms of efficacy between mesalazine preparations so the choice of formulation should depend on factors that may aid adherence to therapy, and the proximal extent of the inflammation 1,7. Page 4
5 Contraindications 1,8 : Hypersensitivity to salicylate Hypersensitivity to sulphonamide/co-trimoxazole Side Effects 1,8 : The most common and dose related side effects are headaches, rash, nausea, epigastric pain and diarrhoea. Side effects that occur rarely include: - Skin disorders (Steven Johnson Syndrome, lupus erythematosis like syndrome); - Blood disorders (agranulocytosis, aplastic anaemia, leucopenia, methaemoglobinaemia, neutropenia, and thrombocytopenia); - Lung disorders (fibrosing alveolitis, eosinophilia); - Renal impairment (interstitial & nephritic syndrome) Others include acute pancreatitis, hepatitis, myocarditis, pericarditis, alopecia, and peripheral neuropathy. Sulphasalazine is associated with a reversible reduction in male fertility, yellow-orange discoloration of skin, urine, and other body fluids. Cautions 1,8 : Renal impairment (See Table 2 -Monitoring) Avoid in patients with severe renal failure. Discuss with renal team if appropriate. Blood disorder Patients should be advised to report any unexplained bleeding, bruising, purpura, sore throat, fever or malaise that occurs during treatment. Hepatic impairment Elderly History of allergy or asthma (Sulphasalazine, Basalazide) Glucose 6 phosphate dehydrogenase deficiency (Sulphasalazine may cause haemolysis) Page 5
6 Interactions 1,8 : Concurrent use of other known nephrotoxic agents, such as NSAIDs and azathioprine, may increase the risk of renal toxicity. Sulfasalazine may reduce absorption of digoxin and folate. Concomitant treatment in patients receiving azathioprine can increase the risk of blood dyscrasias. Asacol MR, Ipocol, Salofolk should not be given with lactulose or similar preparations which lower the stool ph and may prevent the release of mesalazine. For further information about cautions, side effects and interactions for individual drug, please see individual summary product characteristic accessible via medicines.org.uk or contact pharmacy medicines information on ext Pregnancy/ Breastfeeding: Careful assessment of risk versus benefit should be carried out before use during pregnancy and breastfeeding. Consult specialists for further advice. Consider folate acid supplementation during pregnancy in high-risk individuals such as for those taking sulphasalazine 1. Duration of treatment: Lifelong maintenance therapy is recommended for all patients with Ulcerative Colitis especially those with left sided disease or extensive disease who relapse more than once a year. Those with distal disease who have been in remission for 2 years should have a discontinuation assessment performed. However, it is suggested that maintenance therapy reduces the risk of colorectal cancer 4,9. There is limited evidence to support the use of 5ASA s in Crohn's disease however current BSG guidelines (2004) recommend there use in mild ileocolonic disease. The 5-ASA drugs are of little benefit for either inducing remission, or maintaining medically-induced remission. They may be of use for maintenance of surgically-induced remission 3, 13. Page 6
7 Recommended monitoring schedule 1,10,11 : Table 2 Pre-treatment assessment Monitoring Following dose change FBC, U&E, LFT FBC & LFT at 1 month FBC, U&E, Creatinine, LFT at 3 months of then every six months Repeat FBC, LFT, U&E 1 month after increase. If results stable repeat FBC, U&E s and LFT s once yearly Actions to be taken 10 : Table 3 Nausea, dizziness, headache, worsening diarrhoea WBC < 4.0 x 10 9 /l Neutrophils < 2.0 x 10 9 /l Platelets < 150 x 10 9 /l Severe abdominal pain > 2 fold rise above upper limit of normal reference range for ALT(0-45 U/L), AST (0-35 U/L) Rise of creatinine level above the If troublesome, reduce or stop treatment and consider alternative Refer to hospital specialist team. Monitor carefully if WBC continues to fall, withhold until discussed with Gastroenterologist Monitor carefully if neutrophil count continues to fall, withhold until discussed with Gastroenterologist Monitor carefully if platelet count continues to fall, withhold until discussed with Gastroenterologist Check amylase level; Withhold and consider ultrasound or CT scanning Withhold until discussed with specialist team; Ultrasound liver. Withhold until discussed with Page 7
8 normal range (or rise of > 20% compared to baseline) Abnormal bruising or severe sore throat Unexplained acute widespread rash specialist team; Urinalysis for proteinuria etc.; renal ultrasound; nephrology opinion. Check FBC immediately and withhold until result available. Discuss with Gastroenterologist Withhold; seek urgent specialist (preferably Dermatological) advice Dosage & individual treatment 1 NOTE: If no symptomatic improvement is evident after 2 weeks on the maximum dose of either oral or PR medication treatment escalation is necessary 2 Table 4 : Oral formulation Name Maintenance dose for UC Treatment dose for active UC Pentasa (tablets/granules) 2g daily 4g daily (in 2-4 divided doses) Use in CD Octasa g once daily (or in divided doses) g once daily (or in divided doses) Maintenance of remission: g once daily, alternatively daily in divided doses Salofalk (tablets/granules) 500mg TDS 1.5-3g daily, preferably in the morning (or 0.5-1g TDS) Asacol MR *Restricted to existing patients only g daily (in divided doses) Max 4.8g daily (in divided doses) Maintenance of remission: Up to 2.4 g daily in divided doses Page 8
9 Balsalazide Olsalazine (Non-formulary) 1.5g BD (max. per dose 3g) Max. 6g per day 500mg BD after food 2.25g TDS Maximum dose for 12/52. 1 g daily in divided doses taken after meals. Dose may be titrated upwards over a period of one week to a maximum of 3 g daily. A single dose should not exceed 1 g. Sulphasalazine (Nonformulary) 500mg QDS Max 8g daily (1-2g QDS) Active CD: 1 2 g QDS Table 5: Rectal Medication Name Pentasa Suppository Maintenance dose for UC 1g daily Treatment dose for active UC Max 1g at night for up to 2-4 weeks. Use in CD unlicensed Continue for 2/52 after symptomatic relief occurs then taper to stop Pentasa liquid enema (retention) 1g at night 1g at night unlicensed Salofalk Enema 2g at night 2g at night unlicensed Salofalk Rectal Foam unlicensed 2g at night (or in 2 divided doses) unlicensed Page 9
10 Salofalk Suppositories unlicensed Max g, 2-3 times a day, adjusted according to response. unlicensed Asacol Suppository g daily in divided doses. Last dose to be administered at bedtime g daily in divided doses. Last dose to be administered at bedtime unlicensed Asacol Foam Enema unlicensed 1-2g daily for 4-6 weeks unlicensed Sulphasalazine suppositories 0.5-1g BD Administered alone or in conjunction with oral therapy, morning and night after a bowel movement 0.5-1g BD Active Crohn s disease 0.5 1g BD References 1. Joint Formulary Committee. British National Formulary. 74th ed. London: BMJ Publishing Group and Royal Pharmaceutical Society. Nov Accessed 01/11/2017. Available online at 2. National Institute for Health and Care Excellence (NICE) Clinical Guideline 166. Ulcerative colitis; Management in adults, children and young people. June Accessed 09/01/2017. Available online at 3. National Institute for Health and Care Excellence (NICE) Clinical Guideline 152. Crohn s disease; Management in adults, children and young people. October Accessed 09/01/2017. Available online at 4. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults for the BSG. Gut 2011; 60 (5): Accessed 09/01/2017. Available online at Page 10
11 011.pdf 5. The second European evidence based consensus on the diagnosis & management of Crohn s disease: current management National Institute for Health and Care Excellence (NICE) Clinical Knowledge Summaries. Ulcerative colitis. Accessed 09/01/2017. Available online via 7. Smith K. UKMi Q&A What are the differences between different brands of mesalazine tablets? 1 May Accessed 09/01/2017. Available online at European evidence based consensus on the management of Ulcerative colitis Disease Modifying Drugs in Inflammatory Bowel Disease. Written by Dr A.F. Muller On behalf on the Inflammatory Bowel Disease Committee of the British Society of Gastroenterology. Accessed 09/01/17. Available online Crohn s and Colitis UK. 12. Summary of Product Characteristics Asacol 800mg MR tablets. Warner Chilcott UK Limited. Last updated 14-Apr Accessed via on 09/01/ National Institute for Health and Care Excellence (NICE) Clinical Knowledge Summaries. Crohn s Disease. Accessed 09/01/2017. Available online via Suggestions for Drug Monitoring in Adults in Primary Care. February A collaboration between London and South East Medicine Information Service, South West Medicine Information Service and Croydon Clinical Commissioning Group. Accessed 09/01/17. Available online ug%20monitoring%20document%20feb% pdf 15. K. Chakravarty et.al. BSR/BHPR guideline for disease-modifying antirheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. British Healthcare Professionals of Rheumatology. Page 11
12 16. Nottinghamshire Joint Formulary. Accessed on 09/01/17. Available on European Crohn s & Colitis Organisation E-Guide. Accessed on 09/01/17. Available on Page 12
Doncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 1.5 Chronic Bowel Disorders (including IBD) Aminosalicylates: Mesalazine 400mg and 800mg MR Tablets (Octasa) Mesalazine 1.2g MR Tablets (Mezavant XL) Mesalazine
More informationSULFASALAZINE (Adults)
Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationName of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008
Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED
More informationShared Care Guideline
Shared Care Guideline Mercaptopurine inflammatory bowel disease Executive Summary Unlicensed indication, but widely established use of mercaptopurine. Dosing: 25mg daily for two weeks, then 1-1.5mg/kg
More informationWestern Locality Shared care information ~ Azathioprine and Mercaptopurine
The following guidelines are currently under review. In the interim, the guidelines remain valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they
More informationNORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE
NORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE http://www.devonpct.nhs.uk/treatments/ne_devon_shared_care_guidelines.aspx#a Azathioprine Treatment of rheumatological conditions
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationAzathioprine Shared Care Guideline for GPs
Indication: Azathioprine Shared Care Guideline for GPs Active rheumatoid arthritis and other types of inflammatory arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, vasculitis
More informationCOLAZIDE PRODUCT INFORMATION NAME OF MEDICINE. Structural Formula: CAS
Colazide Product Information 1/9 COLAZIDE PRODUCT INFORMATION NAME OF MEDICINE Generic Name: balsalazide sodium Structural Formula: CAS 80573-04-2 DESCRIPTION Capsules containing 750 mg balsalazide sodium,
More informationAzathioprine and Mercaptopurine
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationWestern Locality Shared care Information ~ Penicillamine, Rheumatology April 2013
Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant
More informationPrescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationProducts available Methotrexate tablets 2.5mg ONLY (Methotrexate tablets 10mg are NOT recommended as per NPSA guidance 5 ).
Methotrexate Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationMESALO Foam (Mesalazine)
Published on: 10 Jul 2014 MESALO Foam (Mesalazine) Composition MESALO Foam Each actuation delivers: Mesalazine, BP.... 1.0 g White-grayish to slightly reddish-violet, creamy, firm foam. Dosage Form Rectal
More informationPRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD)
PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD) For the latest information on interactions and adverse effects, always consult the latest version of the Summary of
More informationTrust-wide Guideline
Trust-wide Guideline For Shared Care Guidelines for the Use of Leflunomide (Arava ) A guideline recommended for use In: East and North Herts NHS Trust (ENHT) East and North Herts PCT/ENHCCG By: Consultants
More informationDuration of treatment All DMARDs are long term treatments. Clinical benefit may take up to 6 months. 1
Leflunomide Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti Rheumatic
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Drug: Methotrexate Introduction Indication: Licensed: Rheumatoid arthritis, severe psoriasis, severe active juvenile idiopathic arthritis, severe psoriatic arthritis, mild to moderate
More informationV4.1 Amendment to hydroxychloroquine ophthalmology monitoring made. Agreed by Camden Medicines Management Committee: October 2017 August 2017
North Central London Joint Formulary Committee Quick Reference Guide for Primary Care Prescribers Monitoring Disease Modifying Anti-Rheumatic Drugs (DMARDs) Azathioprine, Mercaptopurine, Sulfasalazine,
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationMedical therapies and IBD
Medical therapies and IBD Although there is no cure for IBD, there are many treatment options available. There is no standard treatment for IBD that is effective in all situations or for all patients,
More informationTrust Guideline. for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis. (*ie aged 16 years and over)
Trust Guideline for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis (*ie aged 16 years and over) abc A guideline recommended for use In: Gastroenterology/Medical
More informationAsacol / Mesalazine to Octasa Switch protocol
Asacol / Mesalazine to Octasa Switch protocol Applies to HaRD MMT Technicians, Pharmacists These protocols are produced by the NY&AWC MM team hosted by HaRD CCG for use by their employed MM team members.
More informationPRODUCT INFORMATION (Mesalazine)
MESASAL PRODUCT INFORMATION (Mesalazine) NAME OF THE DRUG MESASAL 5-aminosalicylic acid (5-ASA). Mesalazine has been identified as the active component of sulfasalazine in inflammatory bowel disease and
More informationGreater Manchester Interface Prescribing Group Shared Care Template
Greater Manchester Interface Prescribing Group Shared Care Template Shared Care Guideline for Azathioprine and 6-Mercaptopurine for Chronic Inflammatory Bowel Disease Author(s)/Originator(s): (please state
More informationShared care guidelines for azathioprine in adults. General principles. Presentation/Dose/Administration Oral: 25mg and 50mg tablets
Shared care guidelines for azathioprine in adults General principles This agreement outlines suggested ways in which the responsibilities for managing the prescribing of the drug treatment and clinical
More informationDMARDS MONITORING GUIDELINES SELKIRK MEDICAL PRACTICE
DMARDS MONITORING GUIDELINES SELKIRK MEDICAL PRACTICE LIST OF DRUGS INCLUDED: ACITRETIN (Neotigason) ADALIMUMAB AMIODARONE AMISULPIRIDE ARIPRAZOLE AZATHIOPRINE CICLOSPORIN CYCLOPHOSPHAMIDE CLOZAPINE DENOSUMAB
More informationHYDROXYCARBAMIDE for Haematological conditions (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: HYDROXYCARBAMIDE for Haematological conditions (Adults) Indication: Hydroxycarbamide is an established treatment in haematological
More informationTreating inflammatory bowel disease
Treating inflammatory bowel disease Topical mesalazine (Enema and Suppository) Information for patients Gastroenterology page 2 of 8 What is my medicine? Mesalazine enemas and suppositories are used in
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationEffective Shared Care Agreement (ESCA)
Effective Shared Care Agreement (ESCA) Azathioprine (either alone or more usually in combination with corticosteroids and/or other drugs and procedures) ESCA: For the treatment of systemic lupus erythematosus
More informationShared Care Guideline Stepping Hill Hospital and North Derbyshire CCG
Shared Care Guideline Stepping Hill Hospital and North Derbyshire CCG Shared Care Guideline for Sulfasalazine in Rheumatological Conditions in Adults Reference Number Replaces: Issue date: November 2017
More informationGreater Manchester Interface Prescribing Group Shared Care Template
Greater Manchester Interface Prescribing Group Shared Care Template Shared Care Guideline for Oral Methotrexate for Rheumatological Conditions Author(s)/Originator(s): (please state author name and department)
More informationFactsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C)
North Central London Joint Formulary Committee Factsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C) Start date: September 2018 Review date: September 2021 Document
More informationSHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More informationPRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis
PRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis For the latest information on interactions and adverse effects, always consult the latest version of the Summary of Product Characteristics
More informationShared Care Guideline
Shared Care Guideline Thiopurine treatment for paediatric gastroenterology and hepatology patients 1. Scope Prescribing and monitoring of thiopurine treatment of Paediatric gastroenterology and hepatology
More informationTreatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis
Treatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis This protocol provides monitoring guidance for adult patients requiring Dimethyl fumarate therapy
More informationEFFECTIVE SHARED CARE AGREEMENT (ESCA)
EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: HYDROXYCHLOROQUINE INDICATION/S COVERED: active rheumatoid arthritis, juvenile idiopathic arthritis, discoid and systemic lupus erythematosus Coastal West
More informationNew Zealand Datasheet
New Zealand Datasheet Name of Medicine DIPENTUM Olsalazine sodium 250mg capsules, 500mg tablets. Presentation 250 mg capsules: Beige, opaque, hard, gelatin capsules size 1, filled with yellow powder and
More informationCiclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml
Shared Care Protocol Ciclosporin for the treatment of rheumatoid arthritis Name of drug, form and strength Background Ciclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml Ciclosporin
More informationShared Care Guideline. Prescribing and Monitoring of oral METHOTREXATE in adults Licensed and off-label indications
North Central London Joint Formulary Committee Shared Care Guideline Prescribing and Monitoring of oral METHOTREXATE in adults Licensed and off-label indications Dear GP, Progressing to a stable, optimal
More informationShared Care Agreement Methotrexate Oral and Subcutaneous For the use in gastroenterology, dermatology and rheumatology
Shared Care Agreement Methotrexate Oral and Subcutaneous For the use in gastroenterology, dermatology and rheumatology Principles of Shared Care Shared care is the mechanism of sharing patient care between
More informationSHARED CARE AGREEMENT: METHOTREXATE S/C
NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) and BSR Guideline for disease-modifying anti-rheumatic drug (DMARD) therapy (available at www.rheumatology.org.uk/resources/guidelines/bsr_guidelines.aspx
More informationPRODUCT INFORMATION DIPENTUM
PRODUCT INFORMATION DIPENTUM NAME OF THE MEDICINE:- Olsalazine sodium. DESCRIPTION:- Composition Active ingredient: Excipients: olsalazine sodium 250 mg capsule - magnesium stearate, gelatin capsule shells;
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Asacol 800mg MR tablets (mesalazine)
PACKAGE LEAFLET: INFORMATION FOR THE USER Asacol 800mg MR tablets (mesalazine) Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again.
More informationWHAT IF WE HAVE A FUN DAY WITHOUT UC GETTING IN THE WAY? INDICATIONS IMPORTANT RISK INFORMATION
WHAT IF WE HAVE A FUN DAY WITHOUT UC GETTING IN THE WAY? Learn how DELZICOL can help you manage your ulcerative colitis INDICATIONS DELZICOL (mesalamine) delayed-release capsules is a prescription medication
More informationShared Care Guideline Stepping Hill Hospital and North Derbyshire CCG
Shared Care Guideline Stepping Hill Hospital and North Derbyshire CCG Rheumatological Conditions in Adults Reference Number Replaces: Issue date: November 2017 Author(s)/Originator(s): (please state author
More informationSULFASALAZIN 500mg enteric-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER SULFASALAZIN 500mg enteric-coated tablets SULFASALAZINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a
More informationAction Pharmacotherapeutic group: Intestinal antiinflammatory agents; aminosalicylic acid and similar agents.
Rafassal caplets, supp, enema -DL-May 2015-02 Doctor leaflet Rafassal Caplets, Suppositories, Enemas Composition Rafassal Caplets: Active ingredient: Rafassal 500 mg Caplets: Each caplet contains mesalazine
More informationEFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: AZATHIOPRINE INDICATION/S COVERED: FOR RHEUMATOLOGY AND DERMATOLOGY
WORKING IN PARTNERSHIP WITH Coastal West Sussex Traffic Light system classification: Amber N.B. The eligibility criteria included here apply to new patients commencing treatment under this agreement &
More informationLEFLUNOMIDE FOR USE IN RHEUMATOLOGY & PAEDIATRIC RHEUMATOLOGY Shared Care Protocol
Oxfordshire Clinical Commissioning Group LEFLUNOMIDE FOR USE IN RHEUMATOLOGY & PAEDIATRIC RHEUMATOLOGY Shared Care Protocol This protocol provides prescribing and monitoring guidance for leflunomide therapy.
More informationInflammatory bowel disease. Kawa Obeid, PhD
Inflammatory bowel disease Kawa Obeid, PhD 63 Introduction Inflammatory bowel disease (IBD) can be divided into two chronic inflammatory disorders of the gastro- intestinal tract, namely Crohn's disease
More informationMycophenolate Mofetil (MMF)
SCG: For Transplant patients The following guidelines are designed to provide information relating to mycophenolate mofetil and to outline the responsibilities of the primary and secondary care teams in
More informationPentasa Sachet 2g. 1. Name of the medicinal product. 2. Qualitative and quantitative composition. 3. Pharmaceutical form. 4. Clinical particulars
Pentasa Sachet 2g Summary of Product Characteristics Updated 17-May-2017 Ferring Pharmaceuticals Ltd 1. Name of the medicinal product PENTASA Sachet 2g prolonged release granules 2. Qualitative and quantitative
More informationPrescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant Patient s Name:.. NHS Number: Patient s Address:...
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationShared Care Protocol Responsibilities
Oxfordshire Clinical Commissioning Group AZATHIOPRINE FOR USE IN RHEUMATOLOGY, DERMATOLOGY, GASTROENTEROLOGY LIVER, NEUROLOGY, RESPIRATORY AND RENAL Shared Care Protocol This protocol provides prescribing
More informationShared Care Guideline Stepping Hill Hospital and North Derbyshire CCG
Shared Care Guideline Stepping Hill Hospital and North Derbyshire CCG Rheumatological Conditions in Adults Reference Number Replaces: Issue date: November 2017 Author(s)/Originator(s): (please state author
More informationMesalazine (5-aminosalicylic acid) 500mg gastro-resistant tablets
Asamax 500 Mesalazine (5-aminosalicylic acid) 500mg gastro-resistant tablets Presentation Asamax 500 gastro-resistant tablet 500 mg: yellow ochre coloured biconvex tablets containing 500 mg mesalazine
More informationCiclosporin for Rheumatology and Dermatology use (Adults)
Shared Care Guideline Ciclosporin for Rheumatology and Dermatology use (Adults) Introduction This shared care agreement outlines the responsibilities between the specialist and the generalist for managing
More informationMETHOTREXATE (Adults)
Shared Care Guideline Methotrexate (Adults) Contents Introduction:... 1 Contraindications & Warnings:... 2 Interactions:... 3 Adverse Effects:... 3 Responsibilities of the specialist initiating treatment:...
More informationInfliximab (Remicade) for paediatric ulcerative colitis - second line
Infliximab (Remicade) for paediatric ulcerative colitis - second line September 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationpatient group direction
NAPROXEN v01 1/10 NAPROXEN PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationPackage leaflet: Information for the user. Octasa 800 mg Modified Release Tablets Active substance: mesalazine
Package leaflet: Information for the user Octasa 800 mg Modified Release Tablets Active substance: mesalazine Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet.
More informationPanobinostat, Bortezomib and Dexamethasone
Panobinostat, Bortezomib and Dexamethasone Indication Treatment of relapsed/refractory multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory
More informationLung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC) Indication: First line palliative therapy for previously untreated Stage IIIB or IV NSCLC patients Regimen details: Docetaxel
More informationPatient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018
THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG Lancashire North CCG Fylde & Wyre CCG East Lancashire CCG Change history Version
More informationSHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More informationPrimary & Secondary Care Inflammatory Bowel Disease Pathway February 2018
South East London Area Prescribing Committee: Primary & Secondary Care Inflammatory Bowel Disease Pathway February 2018 Developed by: South East London IBD Pathway Development Group Approved: February
More informationGuideline Ulcerative colitis: management
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline Ulcerative colitis: management Draft for consultation, December 0 This guideline covers the care and treatment of adults, children and young
More informationPatient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services
Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services This document authorises the supply and/or administration of Ibuprofen
More informationWeekly oral and subcutaneous methotrexate
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationThis information explains the advice about Crohn's disease that is set out in NICE guideline CG152.
Information for the public Published: 1 October 2012 nice.org.uk About this information NICE guidelines provide advice on the care and support that should be offered to people who use health and care services.
More informationESCA: All non-biological DMARDs (oral/subcutaneous) and agreement for transferring of DMARD Prescribing & Monitoring to GP
ESCA: All non-biological DMARDs (oral/subcutaneous) and agreement for transferring of DMARD Prescribing & Monitoring to GP Dermatology/ Haematology/ Gastroenterology/ Neurology/ Ophthalmology/ Respiratory/
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationASACOL against the benefits expected for you. If you have any concerns about being given this medicine, ask your doctor or pharmacist.
New Zealand Consumer Medicine Information Mesalazine 400mg tablets Mesalazine 800mg tablets Mesalazine 16.67%w/w (500mg) suppositories What is in this leaflet Please read this leaflet carefully before
More informationClinical guideline Published: 10 October 2012 nice.org.uk/guidance/cg152
Crohn's disease: management Clinical guideline Published: 10 October 2012 nice.org.uk/guidance/cg152 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationEast Lancashire Medicines Management Board Shared Care agreement for weekly Methotrexate therapy in long term conditions
East Lancashire Medicines Management Board Shared Care agreement for weekly Methotrexate therapy in long term conditions This shared care agreement outlines the responsibilities for managing the prescribing
More informationSUMMARY OF SHARED CARE PROTOCOL FOR MYCOPHENOLATE MOFETIL (MMF)
SUMMARY OF SHARED CARE PROTOCOL FOR MYCOPHENOLATE MOFETIL (MMF) Please refer to Chester Rheumatology shared care protocol for MMF and separate responsibilities document for full details. Responsibilities
More informationBreast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x 4 (3-weekly) in Early Breast Cancer
Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x Indication: Neoadjuvant or adjuvant therapy for moderate to high risk node positive breast
More informationSHARED CARE ARRANGEMENT for DMARDs
SHARED CARE ARRANGEMENT for DMARDs Azathioprine, Ciclosporin, Leflunomide, Mercaptopurine, Methotrexate, Mycophenolate Mofetil, Penicillamine and Sulfasalazine Version: Date: Author: Status: Comment: 1.2
More information. AREAS OF RESPONSIBILITY FOR SHARED CARE
SHARED CARE GUIDELINE FOR RILUZOLE IN THE MANAGEMENT OF MOTOR NEURONE DISEASE (MND) SPECIFICALLY AMYOTROPHIC LATERAL SCLEROSIS (ALS) INDICATION This shared care guideline has been prepared to support the
More informationShared Care Guideline Metolazone for fluid management in CKD (Adults)
Shared Care Guideline Metolazone for fluid management in CKD (Adults) It is vital for safe and appropriate patient care that there is a clear understanding of where clinical and prescribing responsibility
More informationMETHOTREXATE POLICY. Care of Patients who are taking Methotrexate in Low Immunosuppressant Doses (e.g. weekly oral / s/c / or i/m doses)
METHOTREXATE POLICY Care of Patients who are taking Methotrexate in Low Immunosuppressant Doses (e.g. weekly When using this document please ensure that the version you are using is the most up to date
More informationAtezolizumab Non-small cell lung cancer
Systemic Anti Cancer Treatment Protocol Atezolizumab Non-small cell lung cancer PROTOCOL REF: MPHAATNSCLC (Version No: 1.0) Approved for use in: Locally advanced/metastatic non squamous or squamous non-small
More informationAmy-Jo Hooley Specialist Clinical Pharmacist
Gut Decontamination Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Guideline for the Safe Administration
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: AZATHIOPRINE Protocol number: CV 04
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: AZATHIOPRINE Protocol number: CV 04 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION LIVER
More informationBreast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer
Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Indication: Neoadjuvant therapy for high risk and fit breast cancer patients suitable for
More informationChildren Enteric coated tablet : 1-3 mg/kg per day in divided doses.
Ultrafen Tablet/SR Tablet/Suppository/Gel Description Ultrafen is a preparation of Diclofenac is a non-steroidal antiinflammatory agent with marked analgesic, anti-inflammatory and antipyretic properties.
More informationTop Clinical Tips for Inflammatory Bowel Disease
Job bag number: UK/AS/0165/07-13 Date of preparation: July 2013 Top Clinical Tips for Inflammatory Bowel Disease Dr Ayesha Akbar Consultant Gastroenterologist Honorary Senior Lecturer Contents-focus on
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: MYCOPHENOLATE MOFETIL/SODIUM Protocol number: CV 15
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: MYCOPHENOLATE MOFETIL/SODIUM Protocol number: CV 15 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION
More informationShared Care Protocol Oral methotrexate 2.5mg tablets in dermatology/gastroenterology/rheumatology patients
Shared Care Protocol Oral methotrexate 2.5mg tablets in dermatology/gastroenterology/rheumatology patients Specialist Details Name: Patient Identifier (please include NHS number as minimum) Location: Telephone
More informationOxford Inflammatory Bowel Disease MasterClass The mesalazine chamaeleon
Oxford Inflammatory Bowel Disease MasterClass The mesalazine chamaeleon Ailsa Hart Lead IBD Unit, St Mark s Hospital Senior Clinical lecturer Imperial College, London Oxford Inflammatory Bowel Disease
More information